Citius Oncology, Inc. CTOR Indefinite-Lived Research and Development Assets
Indefinite-Lived Research and Development Assets at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s indefinite-lived research and development assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s indefinite-lived research and development assets?
- Citius Oncology, Inc. (CTOR) reported indefinite-lived research and development assets of $3.19M in Q3 2025.
- What is the long-term trend for Citius Oncology, Inc.'s indefinite-lived research and development assets?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s indefinite-lived research and development assets has grown at a 72.4% compound annual growth rate (CAGR), from $1.07M to $3.19M.
- What does indefinite-lived research and development assets mean?
- These are acquired in-process research and development assets that are not yet subject to amortization because their useful life is indeterminate until the project is completed or abandoned. This balance reflects the company's investment in long-term innovation and future product pipelines. It is a key indicator of the value assigned to potential future revenue streams from R&D activities.